Table 1.
Demographic data of the study population in all patients, patients aged 80 years or older and patients younger than 80 years. Comorbidity profile and tumor-related parameters as well as 90-day mortality and 5-year bladder cancer specific and competing mortality rates were less favorable in patients aged 80 years or older compared with their younger counterparts
| Parameter | Whole sample | < 80 years | 80 years or older | p |
|---|---|---|---|---|
| Sample size | 1184 | 1061 | 123 | – |
| Mean follow-up (censored patients) | 7.4 years | 7.6 years | 3.8 years | – |
| Median follow-up (censored patients) | 6.2 years | 6.5 years | 2.5 years | – |
| Mean age | 68.7 years | 67.1 years | 82.6 years | – |
| Bladder confined disease | 684 (58%) | 629 (59%) | 55 (45%) | 0.0020 |
| Extravesical extension | 500 (42%) | 432 (41%) | 68 (55%) | 0.0020 |
| Positive lymph nodes | 308 (26%) | 272 (26%) | 36 (29%) | 0.38 |
| Extravesical extension or positive lymph nodes | 576 (49%) | 500 (47%) | 76 (62%) | 0.0021 |
| Bladder confined disease and negative lymph nodes | 608 (51%) | 561 (53%) | 47 (38%) | 0.0021 |
| ASA classes 3-4 | 493 (42%) | 421 (40%) | 72 (59%) | < 0.0001 |
| Charlson score 2 or higher | 449 (38%) | 383 (36%) | 66 (54%) | 0.0001 |
| Mean Charlson score | 1.57 | 1.50 | 2.18 | < 0.0001 |
| Median Charlson score | 1.00 | 1.00 | 2.00 | – |
| CCS class 2 or higher | 131 (11%) | 109 (10%) | 22 (18%) | 0.0108 |
| NYHA class 2 or higher | 211 (18%) | 177 (17%) | 34 (28%) | 0.0026 |
| Female patients | 255 (22%) | 206 (19%) | 49 (40%) | < 0.0001 |
| Any neoadjuvant chemotherapy | 55 (5%) | 53 (5%) | 2 (2%) | 0.09 |
| Adjuvant cisplatin-based chemotherapy | 258 (22%) | 257 (24%) | 1 (1%) | < 0.0001 |
| Current smokers | 327 (28%) | 315 (30%) | 12 (10%) | < 0.0001 |
| University degree/master craftsman | 274 (23%) | 250 (24%) | 24 (20%) | 0.31 |
| Mean body mass index | 27.0 kg/m2 | 27.0 kg/m2 | 26.7 kg/m2 | 0.26 |
| Median body mass index | 26.7 kg/m2 | 26.7 kg/m2 | 26.4 kg/m2 | – |
| Continent diversion | 390 (33%) | 388 (37%) | 2 (2%) | < 0.0001 |
| Number of removed lymph nodes (if recorded) | 18.4 | 18.8 | 15.2 | < 0.0001 |
| History of myocardial infarction | 86 (7%) | 72 (7%) | 14 (11%) | 0.06 |
| Diabetes mellitus | 288 (24%) | 250 (24%) | 38 (31%) | 0.07 |
| Lung disease | 218 (18%) | 196 (18%) | 22 (18%) | 0.87 |
| Cerebrovascular disease | 65 (5%) | 56 (5%) | 9 (7%) | 0.35 |
| Peripheral vascular disease | 129 (11%) | 111 (10%) | 18 (15%) | 0.16 |
| Deaths from non-cancer causes | 205 | 170 | 35 | – |
| Deaths from bladder cancer | 372 | 325 | 47 | – |
| Deaths from second cancer | 66 | 64 | 2 | – |
| Deaths from unknown causes | 7 | 5 | 2 | – |
| 90-day mortality | 4.2% | 3.7% | 8.9% | < 0.0001 |
| 5-year bladder cancer-specific mortality | 30.3% | 28.9% | 44.3% | 0.0038 |
| 5-year competing (non-bladder cancer) mortality | 14.1% | 12.5% | 28.7% | 0.0005 |